Product Description

Colorectal cancer (mCRC) is the fourth most common cancer among men and women. About 40 % of mCRC patients have mutations of the KRAS gene in the tumor. Tumors with KRAS mutations in codons 12 or 13 are resistant to anti-EGFR therapy. Accordingly, treatment with drugs for the anti-EGFR therapy of mCRC like Erbitux® or Vectibix® is recommended only for tumors without such mutations. Indications for Testing Targeted therapy of metastatic colorectal cancer (mCRC). Sample Material Fresh tissue Fresh-frozen tissue Formalin fixed paraffin embedded (FFPE) tissue Mutant codon – Nucleotides G12C – TGT G12S – AGT G12R – CGT G12V – GTT G12D – GAT G12A – GCT G13D – GAC